Action Mechanisms of Zhongjing's Antidepressant Prescriptions： A Review / 中国实验方剂学杂志

Depression is a threat to human health due to high incidence， recurrence， and disability rates. At present， the complex etiology and pathogenesis of depression are still unclear， and such hypotheses as monoamine neurotransmitters and their receptor abnormality， hyperactivity of hypothalamic-pituitary-adrenal （HPA） axis， inflammation， and neuron damage and remodeling have been put forward. Anti-depressants developed based on the pathogenesis have a certain effect， but there also exist some problems like low cure rate， poor compliance， relapse after discontinuation， and obvious side effects. According to Zhongjing's theory， depression falls into the categories of depression syndrome， visceral agitation， insomnia， and lily disease， and it is mainly located in the liver， involving the spleen， heart， and kidney. The pathogenesis mainly lies in qi stagnation and zang-fu organ dysfunction. Attention should be focused on regulating qi and relieving depression. Zhongjing's antidepressant prescriptions have exhibited good clinical efficacy in the treatment of depression， reflecting the multi-pathway action advantages of Chinese herbs. Based on the pathogenesis of depression and domestic and foreign literature on the intervention of depression with Zhongjing's prescriptions available in the past 20 years， this paper summarized the mechanisms of Zhongjing's prescriptions against depression from the experimental and clinical research aspects， in order to provide reference for clinical treatment of depression with Zhongjing's prescriptions.

Effect of gualou xiebai (GLXB) decoction on platelet-derived growth factor BB (PDGF-BB) expression in lungs from bleomycin A5 induced pulmonary fibrosis in rats / 中国中药杂志

<p><b>OBJECTIVE</b>To investigate the effect and mechanism of Gualou Xiebai (GLXB) decoction on pulmonary fibrosis.</p><p><b>METHOD</b>Pulmonary fibrosis was induced by bleomycin A5 in SD rats. Rats in treatment group were killed after being treated by GLXB by decoction daily for 28 days. The lungs of all rats were harvested for histopathological studies. The contents of platelet-derived growth factor BB (PDGF-BB) in lungs were measured and compared.</p><p><b>RESULT</b>The contents of PDGF-BB in lungs have increased significantly in model group compared with normal group and treatment group (P<0.05).</p><p><b>CONCLUSION</b>GLXB decoction could significantly alleviate the increased PDGF-BB expression in lungs of pulmonary fibrosis rats.</p>